STAT

JUNE 24, 2025

Today, we talk about the readout of Compass Pathways’ psilocybin trial for major depressive disorder, see more vaccine concern and turnover at the FDA, and report from the American Diabetes Association. 

Vaccines 240

Vaccines Immunity Diabetes Immunization 240

STAT

SEPTEMBER 13, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, and congratulations on making it through another week. She is very likely the cutest and most relatable animal I’ve ever seen.

Diabetes 285

Diabetes Drug Pricing Drug Development 285

STAT

APRIL 17, 2025

A daily pill from Eli Lilly helped patients with type 2 diabetes improve their blood sugar and shed weight, the company said Thursday, results that could propel the next-generation treatment onto the market. Lilly touted that the results of the ACHIEVE-1 trial are the first Phase 3 outcomes for an oral GLP-1 treatment.

Diabetes 321

Diabetes Drug Development 321

STAT

APRIL 3, 2024

The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, like mental health disorders , Alzheimer’s, and even, as new study results suggest — Parkinson’s disease.

Diabetes 363

Diabetes Drug Development 363

STAT

NOVEMBER 13, 2023

PHILADELPHIA – Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

Diabetes 351

Diabetes Drug Development 351

STAT

AUGUST 14, 2024

It’s also the latest attempt to deal with one of the biggest challenges in drug development: What should a company do when it wins big? But inventing a mega-blockbuster — in this case novel drugs that treat obesity and diabetes — brings its own set of issues. Victory is hardly defeat.

Diabetes 359

Diabetes Drug Development 359

STAT

FEBRUARY 26, 2024

Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Diabetes 360

Diabetes Compounding Drug Development 360

STAT

SEPTEMBER 5, 2024

Nearly two decades ago, a small company called Amylin Pharmaceuticals saw that its first commercial product, a diabetes treatment targeting receptors of the amylin hormone, led to weight loss in early clinical trials. The company ultimately didn’t pursue an indication in weight loss. Continue to STAT+ to read the full story…

Diabetes 340

Diabetes Drug Development 340

European Pharmaceutical Review

JUNE 12, 2025

These factors have created an ecosystem that allows MLM to address the challenges of drug development. The automatic generation of molecular structures accelerates drug candidate design by predicting target affinity. Through increased efficiency, MLMs can lower drug development costs.

Drug Development 52

Drug Development Documentation Labelling Diabetes 52

STAT

JUNE 25, 2025

“I’m not sure I fully accept the premise of the question,” Martin Lange, Novo’s head of development, responded.    At the American Diabetes Association meeting in Chicago this week, Novo executives argued the company is not falling behind.

Diabetes 216

Diabetes Drug Development 216

STAT

JUNE 23, 2025

People taking Wegovy alone lost a smaller 16% of their weight, and 72% of that was fat mass, according to results that will be presented Monday at the American Diabetes Association meeting. Ninety-three percent of that was fat mass, and the rest was lean mass.

Diabetes 325

Diabetes Drug Development 325

STAT

OCTOBER 17, 2023

Her team had failed to wrestle a gut hormone called GLP-1 into a new kind of drug for diabetes. Thomsen got right to the point. Management was giving them one more shot. And by them, he meant her. “You need to figure out what to do with GLP-1,” he said. “And it has to be now.”

Diabetes 355

Diabetes Drug Development 355

STAT

OCTOBER 24, 2023

But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

Diabetes 257

Diabetes Drug Development 257

STAT

JULY 17, 2024

after four weeks in patients with obesity who did not have diabetes.   The company said its once-daily pill, called CT-996, led to a placebo-adjusted average weight loss of 6.1%

Diabetes 334

Diabetes Drug Development 334

STAT

DECEMBER 11, 2023

And before the end of the month, Vertex will share results from a mid-stage trial in people with diabetes who have chronic nerve pain. The company will announce data early next year from Phase 3 studies testing the molecule’s effectiveness at treating post-surgical pain.

Diabetes 357

Diabetes Drug Development 357

STAT

OCTOBER 17, 2024

billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition will harm competition and reduce patient access to popular diabetes and weight loss medicines.

Diabetes 274

Diabetes Packaging Drug Pricing Drug Development 274

STAT

JUNE 23, 2023

The full   results,  published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference. The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year.

Diabetes 265

Diabetes Drug Development 265

STAT

JUNE 27, 2023

But Eli Lilly has been following close behind with new treatments, and after dropping result after result from successful trials at the American Diabetes Association conference here this past weekend, the Indianapolis-based drugmaker looks to be gaining an edge over its Danish competitor in the race to supply obesity drugs.

Diabetes 244

Diabetes Drug Development 244

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.

Drug Development 98

Drug Development Diabetes Immunization Immunity 98

STAT

APRIL 12, 2024

Enjoy, and see you soon… Western drug makers are talking to alternative suppliers in response to draft U.S. legislation seeking to restrict an important Chinese drug developer and manufacturer over national security concerns , The Financial Times explains. But be safe. The Biosecure Act would prohibit U.S.

Drug Development 236

Drug Development Diabetes Drug Pricing 236

STAT

JUNE 20, 2024

With the immense demand for GLP-1-based drugs and recurring shortages of the branded treatments, a wide variety of businesses have popped up to offer their own versions of what they claim are GLP-1 drugs. No other company has bid on the contract — to supply 14 million pens for the next three years, at about $2 per pen. The

Diabetes 277

Diabetes Compounding Drug Pricing Drug Development 277

European Pharmaceutical Review

DECEMBER 1, 2023

During CPHI Barcelona, EPR Editor Caroline Peachey asked Anil Kane, Global Head of Technical & Scientific Affairs, Pharma Services, at Thermo Fisher Scientific about the dynamic landscape of pharmaceutical drug development. What are the trends affecting drug development today?

Drug Development 98

Drug Development Dosage Diabetes Process Improvement 98

Express Pharma

DECEMBER 2, 2024

The company’s Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity. Novo Nordisk is leading the pack with four separate products, two apiece in Phase III and Phase II.

Labelling 126

Labelling Diabetes Drug Development 126

STAT

JUNE 26, 2023

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Diabetes 253

Diabetes Drug Development 253

STAT

OCTOBER 27, 2023

The plan is to increase investment in its drug-development pipeline and cut costs, and the split could take place as early as the fourth quarter of 2024. The panel committee reviewed non-clinical, clinical, and post-marketing data of the drugs, and said that no updates to their prescribing information was required at the time.

Diabetes 272

Diabetes Drug Development 272

STAT

JUNE 24, 2024

On top of today’s Alnylam news, we have Congress gearing up to vote on Medicare coverage for multi-cancer screenings and obesity drug coverage. Also, updates on Vertex’s type 1 diabetes cell therapy, and a push for phage therapy. Read the rest…

Diabetes 229

Diabetes Drug Pricing Drug Development 229

STAT

JUNE 20, 2025

In the Phase 1/2 study testing the drug, called amycretin, patients on the highest dose of 60 mg lost on average 24.3% of their weight at 36 weeks, while those on placebo lost 1.1%, according to results published Friday in the Lancet that will also be presented at the American Diabetes Association conference.

Diabetes 204

Diabetes Drug Development 204

STAT

JANUARY 12, 2024

Food and Drug Administration did not find evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions , STAT notes. Novartis backed away from its pursuit of Cytokinetics, putting a damper on the prospects of a deal for the promising heart-drug developer , The Wall Street Journal reports.

Diabetes 270

Diabetes Drug Development 270

STAT

MAY 22, 2023

A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus. Novo Nordisk said it plans to submit oral semaglutide for U.S. approvals later this year. Continue to STAT+ to read the full story…

Diabetes 246

Diabetes Drug Development 246

BioPharma Dive

MAY 29, 2024

An acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.

Drug Development 76

Drug Development Diabetes 76

Pharmaceutical Technology

FEBRUARY 24, 2023

(LAI-287 + semaglutide) is under clinical development by Novo Nordisk and currently in Phase III for Type 2 Diabetes. According to GlobalData, Phase III drugs for Type 2 Diabetes have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Diabetes 72

Diabetes Drug Development 72

STAT

JULY 17, 2024

Patients on insulin fear the GLP-1 gold rush is leaving them behind As Novo Nordisk and Eli Lilly invest billions to scale up manufacturing capacity for their highly profitable GLP-1 drugs, diabetes patients around the world are suddenly facing shortages of various insulin products. Read the rest…

Diabetes 192

Diabetes Drug Pricing Drug Development 192

STAT

OCTOBER 25, 2024

Food and Drug Administration maintains its list of drug shortages and which sources it relies on, an issue that affects a growing number of Americans , STAT explains. Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years.

Compounding 208

Compounding Compounding Pharmacies Diabetes Drug Development 208

STAT

JUNE 23, 2025

Today, we get deeper into the ousting of Nicole Verdun at the FDA, see promise from Vertex’s cell therapy for diabetes, and unpack the story of developing the newly approved Gilead PrEP drug lenacapivir. Good morning!

Compounding 154

Compounding Diabetes Drug Pricing Drug Development 154

PharmExec

OCTOBER 31, 2023

Collaboration aims to expand space research in studies of heart disease and diabetes.

Drug Development 52

Drug Development Diabetes 52

PharmExec

OCTOBER 31, 2023

Collaboration aims to expand space research in studies of heart disease and diabetes.

Drug Development 52

Drug Development Diabetes 52

Express Pharma

JULY 1, 2024

Momna Ali, Healthcare Analyst at GlobalData, states, “Amylyx’s acquisition of avexitide marks its entry into the drug development field for metabolic diseases, a departure from its prior focus on neurodegenerative diseases. This shift in strategy comes after Relyvrio’s disappointing efficacy results from the drug’s confirmatory trial.

Labelling 104

Labelling Diabetes Drug Development 104